Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00955409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

BIOLOGICAL: ACC-001(3µg) + QS21
BIOLOGICAL: ACC-001(10µg) + QS21
BIOLOGICAL: ACC-001(30µg) + QS21

Sponsor

Pfizer

Collaborators

[object Object]